Drug-induced hypothermia in stroke models: does it always protect?

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Ischemic stroke is a prevalent neurological disorder with no definitive cure.
• Therapeutic hypothermia shows neuroprotective potential against ischemic brain injury.
• Current hypothermia induction methods lack clinical feasibility for stroke patients.

Purpose of the Study:

• To review pharmacological cooling as a neuroprotective strategy for ischemic stroke.
• To evaluate the neuroprotective effects and complications of various hypothermia-inducing drug classes.
• To guide future clinical trials and animal studies on pharmacological cooling in acute stroke.

Main Methods:

• Review of existing literature on therapeutic hypothermia methods.
• Focus on eight classes of hypothermia-inducing drugs: cannabinoids, opioid receptor activators, transient receptor potential vanilloid, neurotensins, thyroxine derivatives, dopamine receptor activators, hypothermia-inducing gases, adenosine, and adenine nucleotides.
• Assessment of neuroprotective effects and associated complications of these drug classes.

Main Results:

• Pharmacological cooling presents a clinically feasible alternative for inducing therapeutic hypothermia.
• Several drug classes demonstrate potential neuroprotective effects in ischemic stroke models.
• Complications associated with pharmacological cooling require careful consideration for clinical application.

Conclusions:

• Pharmacological cooling is a promising avenue for neuroprotection in acute ischemic stroke.
• Further research and clinical trials are warranted to optimize drug selection and application.
• This review provides a foundation for advancing pharmacological cooling strategies in stroke treatment.